Syncona launches new gene therapy company Beacon Therapeutics
Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2129 entries already.
Entries by Thomas Gabrielczyk
Roche to file MAA for eculizumab competitor
Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.
CGT Catapult expanding with Scotch facility
The world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh.
IZB start-up
At the IZB, we are right in the middle of it allas one of the leading cell culture specialists in the heart of Germany’s biotech hotspot and as a medium manufacturer in life science research.
Supporting Trends in Life Sciences with Simpler Laser Products
“It’s obvious that the overall healthcare market will continue to grow. And photonics technology – which delivers a number of unique capabilities, like non-invasive or non-contact probing at high spatial resolution – is poised to play an ever-increasing role in this field.”
Bayer AG is joining forces with Acuitas Therapeutics Inc
Bayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc.
Cytovation ASA raises US$8m in Series A
Bergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing.
,
Richter-Helm´s Biomanufacturing Facility Expansion progress: inauguration of the new office building
Richter-Helm BioLogics has reached a further and important construction milestone during the expansion of its production site in Bovenau. We officially and ceremoniously inaugurated the new office building on May 31, 2023 together with the mayor of Bovenau, Mr. Ambrock, two years after the groundbreaking ceremony.
Evolution of Antibody Humanization and Affinity Maturation
Antibodies play a vital role in the immune system by providing protection against foreign invaders, such as bacteria and viruses. Produced by B cells, antibodies are protein molecules that can be harnessed to treat cancers, autoimmune disorders, and various infectious diseases. However, the human immune system may recognize modified therapeutic antibodies as foreign substances, reducing their efficacy. To overcome this challenge, the following two processes have been developed: antibody humanization and affinity maturation.
Stem cell gene transfer treats IL-1 immune diseases
Italian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.